Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.35 |
| ▸ | TLR4 | O00206 | 2/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909182 | 0.87 | OPRL1 (0.36) | OPRM1OPRK1OPRL1TLR4CYP2C9 | |
| SCHEMBL2909177 | 0.87 | OPRL1 (0.36) | OPRM1OPRK1OPRL1TLR4CYP2C9 | |
| SCHEMBL14494616 | 0.87 | OPRL1 (0.36) | OPRM1OPRK1OPRL1TLR4CYP2C9 | |
| SCHEMBL2909179 | 0.87 | OPRL1 (0.36) | OPRM1OPRK1OPRL1TLR4CYP2C9 | |
| SCHEMBL20808304 | 0.84 | OPRL1 (0.39) | OPRM1OPRK1OPRL1TLR4CYP2C9 | |
| SCHEMBL20797012 | 0.84 | OPRL1 (0.39) | OPRM1OPRK1OPRL1TLR4CYP2C9 | |
| SCHEMBL20808301 | 0.84 | OPRL1 (0.39) | OPRM1OPRK1OPRL1TLR4CYP2C9 | |
| SCHEMBL20808413 | 0.81 | OPRM1 (0.35) | OPRM1OPRK1OPRL1TLR4 | |
| SCHEMBL20808415 | 0.81 | OPRM1 (0.35) | OPRM1OPRK1OPRL1TLR4 | |
| SCHEMBL20797235 | 0.81 | OPRM1 (0.35) | OPRM1OPRK1OPRL1TLR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221114-B2 | Liquid crystal compound having tetrafluoro cyclohexadiene structure showing negative anisotropy, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2019-03-05 | — | — | US | disclosed |
| US-20160200980-A1 | LIQUID CRYSTAL COMPOUND HAVING TETRAFLUORO CYCLOHEXADIENE STRUCTURE SHOWING NEGATIVE ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-07-14 | — | — | US | disclosed |
| US-20160200980-A1 | LIQUID CRYSTAL COMPOUND HAVING TETRAFLUORO CYCLOHEXADIENE STRUCTURE SHOWING NEGATIVE ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2016-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200980-A1 | LIQUID CRYSTAL COMPOUND HAVING TETRAFLUORO CYCLOHEXADIENE STRUCTURE SHOWING NEGATIVE ANISOTROPY, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | OCIAD2, CNOT1, OCIAD1 | OPRM1 721/4885OPRK1 926/4885OPRL1 1378/4885 |
| US-10221114-B2 | Liquid crystal compound having tetrafluoro cyclohexadiene structure showing negative anisotropy, liquid crystal composition, and liquid crystal display device | OCIAD2, CNOT1, OCIAD1 | OPRM1 721/4885OPRK1 926/4885OPRL1 1378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.